Monopar Therapeutics Inc. (MNPR)
MNPR moved a median of -0.13% 30 minutes after news, and -0.98% by the close. How MNPR actually reacts to news — the realized, point-in-time move the market made, measured across 274 labeled events over the last three years with zero look-ahead.
MNPR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 252 |
| 30-min | -0.13% | 41% | 271 |
| 60-min | -0.77% | 37% | 274 |
| to close | -0.98% | 38% | 266 |
| Middle 50% of MNPR reactions | -1.80% to +1.58% |
|---|---|
| Median reaction (30-min) | -0.13% |
| Measured reactions | 274 |
Half of all Monopar Therapeutics Inc. news events land between -1.80% and +1.58% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MNPR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.51% | 50% | +2.26% |
| Analyst downgrades | 12 | +1.32% | 100% | +0.22% |
| Coverage initiations | 35 | -1.18% | 37% | -0.66% |
| Rating reiterations | 51 | +0.28% | 57% | +0.59% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how MNPR ranks against every other measured name →
That’s how MNPR usually reacts — get an email when it moves on news →Email me when MNPR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MNPR's baseline. Nothing else.
Recent MNPR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026 | Press release | GlobeNewswire | -0.08% | +4.51% | |
| Form 10-Q Monopar Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.21% | -0.25% | |
| Form 8-K Monopar Therapeutics For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | -0.25% | |
| Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | — | -0.25% | |
| Form 8-K Monopar Therapeutics For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.49% | |
| Form S-8 Monopar Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -3.41% | -4.66% | |
| Form S-8 POS Monopar Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -3.41% | -4.66% | |
| Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease | Press release | GlobeNewswire | +0.00% | -0.49% | |
| Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team | Press release | GlobeNewswire | +1.15% | -5.83% | |
| Form 8-K Monopar Therapeutics For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | -3.96% | |
| Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease | Press release | GlobeNewswire | -0.28% | -3.96% | |
| Form 8-K Monopar Therapeutics For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -0.26% | +7.85% | |
| Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease | Press release | GlobeNewswire | -0.26% | +7.85% | |
| Form 8-K Monopar Therapeutics For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +2.88% | +19.88% | |
| Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 | Press release | GlobeNewswire | -0.96% | -0.37% | |
| Form 8-K Monopar Therapeutics For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -0.96% | -0.37% | |
| Form 8-K Monopar Therapeutics For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -1.38% | +16.44% | |
| Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease | Press release | GlobeNewswire | -1.38% | +16.44% | |
| Form 10-Q Monopar Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.60% | +1.62% | |
| Form 8-K Monopar Therapeutics For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | +0.74% | |
| Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +2.02% | +2.63% | |
| Form ARS Monopar Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.15% | +2.19% | |
| Form DEF 14A Monopar Therapeutics For: Jun 22 | SEC filing · Form DEF | SEC EDGAR | -2.15% | +2.19% | |
| Form DEFA14A Monopar Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -2.15% | +2.19% | |
| Form 8-K Monopar Therapeutics For: Apr 19 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | -2.70% | |
| Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 | Press release | GlobeNewswire | -0.39% | -2.70% | |
| Form 10-K/A Monopar Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.10% | -4.10% | |
| Form 10-K Monopar Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.83% | -2.82% | |
| Form 8-K Monopar Therapeutics For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | -3.29% | |
| Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -0.30% | -2.82% | |
| Form 8-K Monopar Therapeutics For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +1.99% | +0.38% | |
| Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer | Press release | GlobeNewswire | +1.99% | +0.38% | |
| Form 10-Q Monopar Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.43% | — | |
| Form 8-K Monopar Therapeutics For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | — | |
| Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments | Press release | GlobeNewswire | +0.43% | — | |
| Form 8-K Monopar Therapeutics For: Nov 09 | SEC filing · Form 8-K | SEC EDGAR | -2.78% | -2.68% | |
| Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 | Press release | GlobeNewswire | -2.78% | -2.68% | |
| Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 | Press release | GlobeNewswire | +0.93% | -6.20% | |
| Form 8-K Monopar Therapeutics For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -1.84% | +3.42% | |
| Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients | Press release | GlobeNewswire | +4.40% | +6.15% | |
| Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +4.40% | +6.15% | |
| Form 8-K Monopar Therapeutics For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +4.95% | |
| Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting | Press release | GlobeNewswire | +0.02% | +4.95% | |
| Form EFFECT Monopar Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -1.51% | |
| Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting | Press release | GlobeNewswire | -1.92% | -0.66% | |
| Form S-3 Monopar Therapeutics | SEC filing · Form S-3 | SEC EDGAR | — | +1.53% | |
| Form 10-Q Monopar Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Monopar Therapeutics For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments | Press release | GlobeNewswire | — | — | |
| Form 8-K Monopar Therapeutics For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MNPR section they belong to.
Where else MNPR is measured.
MNPR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Monopar Therapeutics Inc.'s median reaction calculated?
Every labeled MNPR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 274 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of MNPR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MNPR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.